Biodexa Hits Midpoint in FAP Trial Recruitment Ahead of Schedule
Event summary
- Biodexa has recruited 87 of 168 planned subjects in its Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP), exceeding the halfway point.
- The trial is active at 29 US and European sites, with 3 additional Canadian sites expected to open soon.
- Futility analysis is planned after 25 Progression-Free Survival (PFS) events, with database lock after 75 PFS events.
- eRapa has Orphan Drug Designation in the US and Europe, supported by a $20M grant from the Cancer Prevention and Research Institute of Texas.
The big picture
Biodexa's rapid enrollment in the Serenta trial positions eRapa as a potential first-in-class therapy for FAP, a rare genetic disorder with no approved treatments. The trial's progress is critical for Biodexa's strategic pivot toward gastrointestinal cancers, leveraging its proprietary mTOR inhibitor platform. The $20M CPRIT grant underscores the clinical and commercial potential of eRapa, but success hinges on maintaining recruitment momentum and achieving statistically significant PFS outcomes.
What we're watching
- Trial Execution
- Whether Biodexa can maintain its accelerated recruitment pace to meet the 168-subject target.
- Regulatory Pathway
- The impact of the composite endpoint design on the trial's ability to demonstrate eRapa's efficacy.
- Competitive Positioning
- How Biodexa's progress compares to potential competitors in the FAP treatment space.
Related topics